Jagsonpal completes 77.21 percent acquisition of Aequitas Healthcare

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.2%Reaction day

₹228.80

prior close

₹231.66

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.9%-0.7% vs market

Pharmaceuticals peers, median of 166sector+0.9%+0.3% vs sector

On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

+0.0

15m

+1.2

30m

+1.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.2+1.9-0.7+0.9+0.3

Next day

+1.8+3.3-1.5+1.4+0.5

+0.3+3.5-3.1+1.8-1.4

-1.5+2.4-4.0+1.4-2.9

-1.6+3.1-4.7+1.6-3.2

-1.5+2.6-4.1+1.6-3.0

-2.5+2.1-4.7+1.2-3.8

15d

+1.6+0.9+0.7-0.6+2.3

+2.3+5.5-3.2+0.6+1.7

+2.3+8.1-5.8+2.7-0.4

-1.3+3.5-4.8-0.8-0.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jagsonpal Pharmaceuticals has completed the acquisition of a 77.21 percent equity stake in Aequitas Healthcare Private Limited, which is lower than the originally planned 85 percent stake. The proposed acquisition was first disclosed on June 29, 2026 with an update on July 7, 2026. This filing under SEBI LODR Regulation 30 confirms a slightly scaled down version of the deal, expanding the company presence into the healthcare services space. Details on the remaining stake were not provided.

Likely market impact

Stake acquired is below the originally planned 85 percent. Acquiring 77 percent control still gives meaningful strategic entry into healthcare services.